What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino acid sequence derived from a protective protein found in human gastric juice. Its amino acid sequence is GEPPPGKPADDAGLV, with a molecular weight of 1419.53 g/mol. Unlike many research peptides that are synthetic analogues of human hormones, BPC-157’s parent protein is naturally produced in the gastrointestinal tract, where it plays a role in mucosal integrity and tissue protection.
BPC-157 has been studied extensively in preclinical models for its effects on angiogenesis, wound healing, inflammation, and tissue repair across multiple organ systems. For a comprehensive overview of BPC-157’s mechanisms and research findings, see our BPC-157 Complete Research Guide.
From a dosing perspective, BPC-157’s mechanisms are relevant because they help explain its unusually wide effective dose range. The compound interacts with the nitric oxide (NO) system, upregulates growth factor receptors including VEGFR2 and FGFR2, and modulates the FAK-paxillin pathway involved in cell migration and tissue remodeling. These pleiotropic interactions — acting on multiple pathways simultaneously — may account for why nanogram and microgram doses produce similar biological outcomes in some models. Understanding the mechanism helps researchers anticipate which tissue types and injury models are most likely to respond, and informs BPC-157 dosage selection and timing within a research protocol.
BPC-157 Dosage in Published Research
BPC-157 dosage data comes exclusively from animal studies and in vitro experiments — no human clinical trials have been completed or published in peer-reviewed journals as of 2026. This is an important distinction: all dosage information discussed below is derived from preclinical research, and translation to human equivalents involves significant uncertainty.
Animal study dosages
The majority of published BPC-157 research uses rodent models (rats and mice). Dosages across the literature generally fall within the following ranges:
| Administration Route | Typical Dose Range | Most Common Dose | Frequency |
|---|---|---|---|
| Intraperitoneal (IP) | 10-50 mcg/kg | 10 mcg/kg | Once daily |
| Subcutaneous (SC) | 10-50 mcg/kg | 10 mcg/kg | Once daily |
| Oral (in drinking water) | 10 mcg/kg – 10 ng/kg | 10 mcg/kg | Continuous access |
| Topical (cream) | 1-10 mcg/cm² | Variable | Once or twice daily |
A notable finding across BPC-157 research is the compound’s effectiveness at both microgram (mcg/kg) and nanogram (ng/kg) doses — a 1,000-fold range. This unusually wide effective dose range has been observed in multiple independent studies across different tissue types and injury models, suggesting a mechanism that does not follow simple linear dose-response kinetics.
Calculating human equivalent doses (HED)
The FDA-recommended method for converting animal doses to human equivalent doses uses body surface area (BSA) normalization rather than simple weight-based scaling. For rats, the conversion factor is approximately 6.2 — meaning a rat dose in mg/kg is divided by 6.2 to estimate the human equivalent dose in mg/kg.
| Rat Dose (mcg/kg) | HED (mcg/kg) | HED for 80kg human |
|---|---|---|
| 10 mcg/kg (low end) | 1.6 mcg/kg | ~128 mcg |
| 50 mcg/kg (high end) | 8.1 mcg/kg | ~648 mcg |
These calculations produce estimated human equivalent doses in the range of approximately 100-700 mcg per day. Within the research community, the most commonly discussed doses fall between 200-500 mcg administered once or twice daily via subcutaneous injection.
Dosage by Research Application
Published preclinical studies have investigated BPC-157 across a wide range of tissue types and injury models. The dosing protocols vary by application:
Musculoskeletal and tendon repair
Rodent studies on tendon healing (Achilles tendon transection models) used 10 mcg/kg IP or SC daily, with treatment durations of 14-28 days. Significant improvements in tendon healing, collagen fiber organization, and biomechanical strength were observed. Similar protocols showed accelerated healing in muscle crush injuries, ligament damage, and bone fracture models.
Gastrointestinal protection
Studies on gastric ulcers, inflammatory bowel disease models, and intestinal anastomosis healing typically used 10 mcg/kg IP or oral administration. BPC-157 demonstrated oral stability — an unusual property for a peptide — and showed efficacy when administered in drinking water, suggesting it can survive the gastric environment in bioactive form. For more on BPC-157’s gut health applications, see our Peptides for Gut Health Research Guide.
Wound healing and skin repair
Topical and systemic BPC-157 administration in burn and wound models used 10-50 mcg/kg. A topical BPC-157 cream formulation outperformed silver sulfadiazine (standard burn treatment) in mouse burn studies. For skin-specific peptide research, see our Best Peptides for Skin Research.
Combined with TB-500 (Wolverine Stack)
BPC-157 is frequently studied alongside TB-500 (Thymosin Beta-4) in tissue repair research. BPC-157 promotes angiogenesis and growth factor signaling while TB-500 facilitates actin regulation and cell migration — complementary mechanisms that address different phases of tissue healing. For details on this combination, see our Wolverine Stack: BPC-157 + TB-500 Guide.
Neurological and CNS research
A growing body of preclinical research has examined BPC-157 dosage protocols in neurological injury models, including traumatic brain injury, spinal cord damage, and peripheral nerve crush models. BPC-157 dosage in these studies typically mirrors the standard musculoskeletal range — 10 mcg/kg administered IP or SC once daily — with treatment durations of 14 to 28 days post-injury. Observed outcomes in rodent models include improved motor recovery scores, reduced lesion volume, and enhanced axonal regrowth markers, though these findings remain strictly preclinical.
BPC-157 has also been investigated in models of stress-induced organ damage, including restraint stress, corticosteroid-induced toxicity, and NSAID-induced gastric injury. In these models, the protective and reversive effects of BPC-157 dosage were observed within the same 10 mcg/kg range used in structural injury models, further supporting the broad-spectrum tissue-protective mechanism of this peptide.
Cardiovascular and vascular research
In vascular models, BPC-157 dosage studies have demonstrated acceleration of anastomosis healing, improved collateral vessel formation, and protection against ischemia-reperfusion injury. Effective doses in these models generally fall within 10–50 mcg/kg administered subcutaneously, with angiogenic effects appearing particularly prominent in studies measuring VEGFR2 expression and capillary density at wound sites. These findings are relevant to research on BPC-157 as a vascular support compound, though clinical translation has not yet been established.
Administration Routes
Subcutaneous injection
The most common administration route in research settings. BPC-157 is reconstituted with bacteriostatic water and injected subcutaneously, typically near the area of interest (e.g., near an injured tendon or joint) or in the abdominal area for systemic effects.
Oral administration
BPC-157 demonstrates unusual oral stability for a peptide. Multiple studies have shown efficacy when administered orally in drinking water, with some researchers reporting comparable results to injection routes for gastrointestinal and certain systemic applications. This oral stability is attributed to BPC-157’s origin as a gastric peptide — it evolved to function in the acidic gastric environment.
Intraperitoneal injection
Intraperitoneal (IP) injection is widely used in rodent research due to ease of administration and rapid systemic absorption. While IP injection is a standard route in animal studies, it is not a relevant route in human research contexts. The IP route data is valuable primarily for establishing dose-response relationships and bioavailability profiles in preclinical models, which then inform human equivalent BPC-157 dosage calculations via allometric scaling. Researchers interpreting the animal literature should note that IP and SC routes have produced comparable results in head-to-head comparisons, supporting the use of subcutaneous protocols when extrapolating to human equivalent dose estimates.
Topical application
Topical BPC-157 formulations — typically cream or gel-based vehicles — have been tested in burn wound and skin repair models. In mouse burn studies, a BPC-157 cream was applied directly to wound sites once or twice daily at concentrations providing approximately 1–10 mcg per cm² of wound area. Topical delivery allows localized BPC-157 dosage to superficial tissues without significant systemic exposure. The cream formulation must maintain peptide stability, and research-grade topical preparations require careful formulation to prevent degradation at the application site. Comparative data from the burn studies suggests that topical BPC-157 dosage outperformed silver sulfadiazine, a standard burn treatment, in both healing rate and wound closure metrics.
Reconstitution for Research Use
PSPeptides BPC-157 is supplied as a lyophilized powder. Reconstitute with Hospira bacteriostatic water before use.
For step-by-step reconstitution instructions, see our How to Reconstitute Peptides Guide. Use our free Peptide Reconstitution Calculator to determine exact volumes for your desired concentration.
Duration of Use in Research
Published animal studies range in duration from single-dose acute studies to chronic protocols lasting 30+ days. The most common treatment durations in healing-focused research are:
- Acute injury models: 7-14 days
- Tendon/ligament repair: 14-28 days
- Chronic conditions (GI, inflammation): 28-42 days
- Preventive/protective studies: Duration varies by protocol
No published data establishes maximum safe duration of use. Long-term studies in rats (administered for several months) have not reported significant adverse effects, but these are animal models and may not translate directly.
Safety Observations
Across the published preclinical literature, BPC-157 has demonstrated a remarkably clean safety profile. No organ toxicity, mutagenicity, or significant adverse effects have been reported in animal studies, even at doses substantially above the typical effective range. LD50 (lethal dose) testing has not identified a lethal dose — the compound appears to have an extremely wide therapeutic margin.
However, the absence of human clinical trials means the safety profile in humans remains uncharacterized. For a broader discussion of peptide safety considerations, see our Peptide Side Effects Guide.
Frequently Asked Questions
What is the standard BPC-157 research dose?
The most commonly cited dose in animal research is 10 mcg/kg body weight administered once daily via subcutaneous injection. Using FDA body surface area conversion, this translates to approximately 100-200 mcg per day as a human equivalent estimate.
Can BPC-157 be taken orally?
Unlike most peptides, BPC-157 has demonstrated oral stability and efficacy in multiple animal studies. It originates from gastric juice and appears to retain bioactivity when exposed to stomach acid. Oral and injectable routes have shown comparable results in some GI-related studies.
How long does BPC-157 take to work in research models?
In animal studies, measurable healing improvements are typically observed within 3-7 days, with more substantial structural and functional recovery occurring over 14-28 days. Timeframes vary by tissue type and injury severity.
Should BPC-157 be injected locally or systemically?
Published research has shown efficacy with both local (near the injury site) and systemic (abdominal subcutaneous) injection. Some researchers prefer local injection for musculoskeletal applications and systemic injection for gastrointestinal or multi-site protocols.
Vial Sizes and Concentration Planning for BPC-157 Research
BPC-157 is commonly supplied in lyophilized vial sizes of 2 mg, 5 mg, and 10 mg for research use. Selecting the appropriate vial size and planning the reconstitution volume determines the working concentration and, ultimately, the precision of each BPC-157 dosage. Researchers should calculate their target concentration before reconstitution, as adding the wrong volume of bacteriostatic water will result in doses that deviate significantly from the intended BPC-157 dosage.
| Vial Size | BAC Water Added | Resulting Concentration | Volume per 250 mcg Dose |
|---|---|---|---|
| 5 mg (5,000 mcg) | 2 mL | 2,500 mcg/mL | 0.10 mL (10 IU) |
| 5 mg (5,000 mcg) | 5 mL | 1,000 mcg/mL | 0.25 mL (25 IU) |
| 10 mg (10,000 mcg) | 2 mL | 5,000 mcg/mL | 0.05 mL (5 IU) |
| 10 mg (10,000 mcg) | 10 mL | 1,000 mcg/mL | 0.25 mL (25 IU) |
When planning a BPC-157 dosage protocol, researchers should also account for the stability window of the reconstituted solution. Reconstituted BPC-157 stored in bacteriostatic water at 2–8°C (refrigerator temperature) is generally considered stable for 4–6 weeks. Exposure to light, heat above 25°C, or repeated freeze-thaw cycles can degrade the peptide and reduce the effective BPC-157 dosage per injection below the intended amount. All vials should be stored lyophilized until the date of reconstitution, and each vial should be reconstituted only once for multi-dose use rather than reconstituting partial vials on multiple occasions.
For precise dosage calculations tailored to your specific vial size and desired concentration, use our free Peptide Reconstitution Calculator. This tool eliminates manual calculation errors and ensures each BPC-157 dosage in your research protocol is consistent across the full study duration.
References
- Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865.
- Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des. 2018;24(18):1972-1989.
- Chang CH, et al. BPC-157 Promotes Muscle Regeneration. J Orthopaedic Research. 2021;39(12):2628-2637.
- Cesarec V, et al. Pentadecapeptide BPC 157 and the esophagus. Eur J Pharmacol. 2013;701(1-3):150-155.
- Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31.
Buy Research-Grade BPC-157 → | Buy BAC Water → | Buy Syringes →
This content is for educational and research purposes only. All products are intended for laboratory research use only. Not for human consumption.
What is the standard BPC-157 dosage used in research?
In preclinical research studies, BPC-157 dosage typically ranges from 1–10 µg/kg of body weight, administered via subcutaneous or intraperitoneal injection. When converted to human equivalent doses, this translates to approximately 250–500 mcg per day, which is the range most commonly referenced in research protocols. The BPC-157 dosage may be adjusted based on the specific research objectives and the target tissue being studied.
How long should a BPC-157 dosage cycle last?
Most BPC-157 research protocols run for 4–6 weeks, followed by an equal off-period before resuming. Shorter cycles of 2–4 weeks have been used in studies focusing on acute tissue injury, while longer protocols may be considered for chronic conditions. Cycling BPC-157 dosage helps researchers evaluate both the acute and sustained effects of the peptide on tissue repair.
Should BPC-157 be injected or taken orally?
BPC-157 has demonstrated activity through both oral and injectable administration routes in animal studies. Subcutaneous injection near the target tissue is the most common method in research settings because it provides localized delivery and more predictable bioavailability. Oral BPC-157 dosage has shown particular promise in gastrointestinal studies, as the peptide is remarkably stable in stomach acid.
What is the difference between BPC-157 dosage in mcg and mg?
BPC-157 dosage is typically measured in micrograms (mcg), where 1 mg equals 1,000 mcg. A common research dose of 250–500 mcg is therefore 0.25–0.5 mg, which is an important distinction when reconstituting lyophilized peptide vials. Accurate BPC-157 dosage calculation requires understanding this conversion, especially when working with 5 mg or 10 mg vials reconstituted with bacteriostatic water.
Can BPC-157 and TB-500 be dosed together?
BPC-157 and TB-500 are frequently combined in research protocols because they target complementary phases of tissue repair. In combined studies, each peptide is typically dosed at its standard individual range—BPC-157 at 250–500 mcg and TB-500 at 2–5 mg per dose. This combination, sometimes called the Wolverine Stack, allows researchers to study synergistic effects on angiogenesis, cell migration, and collagen remodeling simultaneously.
How do you calculate BPC-157 dosage from a reconstituted vial?
To calculate BPC-157 dosage from a reconstituted vial, divide the total peptide content by the volume of bacteriostatic water used. For example, a 5 mg vial reconstituted with 2 mL of BAC water yields a concentration of 2,500 mcg/mL, meaning 0.1 mL (10 units on an insulin syringe) delivers 250 mcg. Proper reconstitution and dosage calculation are critical for maintaining consistency across research protocols.
Does BPC-157 dosage vary by body weight?
In animal studies, BPC-157 dosage is calculated based on body weight, typically at 1–10 µg per kilogram. When scaling to human equivalent doses using allometric conversion factors, most research references settle on a flat range of 250–500 mcg regardless of body weight. However, some research protocols do adjust the BPC-157 dosage proportionally for subjects at the extremes of the weight spectrum.